⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 28, 2011Journal of Clinical OncologyOpen Access

Prognostic Validity of a Novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine Tumors

Jonathan Strosberg Asima Cheema Jill Weber Gang Han Domenico Coppola Larry K. Kvols

View Full Paper

Ask AI

Bookmark

Share

Abstract

The AJCC TNM classification for pancreatic NETs is prognostic for OS and can be adopted in clinical practice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Strosberg et al. (2011) studied this question.

synapsesocial.com/papers/69dff53993e101b251e9c0fe https://doi.org/10.1200/jco.2011.35.1817

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Differences in Survival by Histologic Type of Pancreatic CancerOriginal Research · 2005 · 270 citations
2One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesPrognostic Study · 2008 · 4,512 citations
3Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumorsPrognostic Study · 2008 · 374 citations
4TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemOriginal Research · 2006 · 1,548 citations
5Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumorsPrognostic Study · 2008 · 405 citations

More related papers

The Secret of Immortal Time Bias in Epidemiologic Studies2008
Application of the Pancreatic Adenocarcinoma Staging System to Pancreatic Neuroendocrine Tumors2007

More from Journal of Clinical Oncology

COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerSat,
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final AnalysisSat,
ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate CancerSat,